-
EP4255497
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4255497
| EP4255497 - MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 08.09.2023 Database last updated on 02.09.2024 | |
| Former | The international publication has been made Status updated on 14.06.2022 | Most recent event Tooltip | 09.02.2024 | Change: Validation states | published on 13.03.2024 [2024/11] | 09.02.2024 | Change - extension states | published on 13.03.2024 [2024/11] | Applicant(s) | For all designated states Seagen Inc. 21823 30th Drive S.E. Bothell, WA 98021 / US | [2023/41] | Inventor(s) | 01 /
HEISER, Ryan A. Bothell, Washington 98021 / US | 02 /
GROGAN, Bryan M. Bothell, Washington 98021 / US | [2023/41] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [2023/41] | Application number, filing date | 21901484.2 | 02.12.2021 | [2023/41] | WO2021US61660 | Priority number, date | US202063121044P | 03.12.2020 Original published format: US 202063121044 P | [2023/41] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022120084 | Date: | 09.06.2022 | Language: | EN | [2022/23] | Type: | A1 Application with search report | No.: | EP4255497 | Date: | 11.10.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 09.06.2022 takes the place of the publication of the European patent application. | [2023/41] | Search report(s) | International search report - published on: | US | 09.06.2022 | Classification | IPC: | A61K47/68, A61P35/02, C07K16/28 | [2023/41] | CPC: |
C07K16/2878 (EP,IL,KR,US);
A61K47/6849 (EP,IL,KR);
A61K47/6803 (IL,KR);
A61K47/68037 (EP,US);
A61K47/6851 (KR);
A61K47/6889 (EP,IL);
A61P35/00 (KR);
A61P35/02 (EP,IL,KR);
A61P35/04 (US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/41] | Title | German: | MODULATION DER IMMUNANTWORT MIT ANTI-CD30-ANTIKÖRPER-WIRKSTOFF-KONJUGATEN | [2023/41] | English: | MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES | [2023/41] | French: | MODULATION DE LA RÉPONSE IMMUNITAIRE À L'AIDE DE CONJUGUÉS ANTICORPS-MÉDICAMENT ANTI-CD30 | [2023/41] | Entry into regional phase | 13.06.2023 | National basic fee paid | 13.06.2023 | Search fee paid | 13.06.2023 | Designation fee(s) paid | 13.06.2023 | Examination fee paid | Examination procedure | 13.06.2023 | Examination requested [2023/41] | 11.01.2024 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.12.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2007044616 (XENCOR INC [US], et al); | [A]WO2019089870 (SEATTLE GENETICS INC [US]); | [A]US2020239585 (HEISER RYAN [US], et al); |